Wet Age-Related Macular Degeneration Market Share Analysis of the Top Industry Players

The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&S Intelligence.

Lucentis, Eylea, and Avastin are the key drugs available globally for the management of wet AMD. Among these, Eylea is expected to dominate the market during the forecast period. Increasing prevalence of AMD and rise in demand for Eylea are some of the major factors propelling the demand for this drug in the wet age-related macular degeneration market.

Based on the route of administration, the wet age-related macular degeneration market is bifurcated into intravitreally and intravenously administered drugs. During the forecast period, the market is expected to witness faster growth in the category of drugs administered through the intravitreal route, with 7.2% CAGR.

During the forecast period, the wet age-related macular degeneration market is expected to witness the fastest growth in APAC, with 8.8% CAGR. The growth in the APAC wet age-related macular degeneration industry is mainly led by the surge in geriatric population, rise in prevalence of AMD, and medical reimbursements provided by the government for the treatment in the region.

Request to Get the Sample Pages at:  

http://bit.ly/wet-age-related-macular-degeneration-market-b

APAC accounts for more than one-third of the macular generation cases reported globally, which is expected to further increase in the coming years. According to the United Nations projections, around 24% of Asians will be aged 60 years or older by 2050. Since the elderly are at a higher risk of developing AMD, the demand for the required medication for the treatment of the disease is expected to considerably increase in the region in the coming years.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=wet-age-related-macular-degeneration-market

Globally, the wet age-related macular degeneration market is witnessing rapid evolution with a substantial increase in the number of clinical trials conducted for wet AMD drugs. For instance, in February 2019, Outlook Therapeutics Inc. initiated a clinical study to examine the efficacy and safety of ONS-5010 in subjects with wet AMD. The aim of the study is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared to ranibizumab’s.

The global wet age-related macular degeneration market is marked by the presence of several large players, such as Regeneron Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Kubota Pharmaceutical Holdings Co. Ltd., Gilead Sciences Inc., Novartis AG, Alimera Sciences Inc., and Bayer AG.

Biosimilars Market Analysis by Stages, Drug Class, and Phase of Development

The market is majorly driven by rising prevalence of chronic diseases, increasing investment in research and development (R&D) activities by biopharmaceutical companies, extensive pipeline of biosimilars, growing geriatric population, and inexpensive nature of biosimilars as compared to reference drugs.

< href="http://bit.ly/biosimilars-b">

On the basis of technology, the biosimilars market is categorized into five categories, such as monoclonal antibody (mAb), recombinant deoxyribonucleic acid (rDNA), bioassays, nuclear magnetic resonance (NMR), and electrophoresis. Biosimilars manufactured using mAb technology held the largest share, of 56%, in 2018. This technology is also expected to be the fastest growing category in the market, owing to large development of therapeutics with the help of this technology for various diseases such as cancer, immunological, and infectious diseases.

Moreover, companies in North America are more independent for pricing their products as compared to other regions, and trained scientific personnel and advanced technologies are readily accessible in North America, which make the region more suitable for pharmaceutical companies.

Request to Get the Sample Pages at:

New product launches and strategic collaborations play an important role in expansion of the biosimilars market. For instance, Amgen Inc. and EnteraBio Ltd. announced a collaboration to develop orally-administered formulation of biologics in 2018. This shows that companies are willing to invest in biologics, which in turn, is expected to be a major driving factor for the growth of the market.

Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the biosimilar business in China. Through the partnership, Samsung Bioepis Co. Ltd. will be able to widen its biosimilars portfolio and 3SBio Group will be benefited from the sales of Avastin.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biosimilars-market

In another strategic move, Celltrion Inc. in partnership with Teva Pharmaceutical Industries Ltd. announced the approval of Herceptin’s biosimilar, Herzuma, in October 2016. As a result, both companies got benefit from the sales of Herzuma. Also, Amgen Inc., Sandoz International GmbH, Samsung Bioepis, and Mylan N.V. jointly launched adalimumab in 2018 in the European biosimilars market and they are expected to launch this biosimilar in the U.S. market by 2023.

Some of the key players in the global biosimilars market are AMEGA Biotech, Samsung Bioepis Co. Ltd., Coherus BioSciences Inc., Synthon Holding B.V., BIOCAD, Zydus Cadila, Celltrion Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., and Mylan N.V.

Dermatology Drugs Market And its Growth prospect in the Near Future

Dermatology drugs market is expected to reach $34.5 billion by 2023, according to P&S Intelligence.Increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally.

Major therapy areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars, and skin cancer. The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period. The category generated revenue of $14.2 billion in the market in 2017. The report also provides the analysis of various therapy areas, on the basis of prescription mode.

On the basis of prescription mode, the market has been categorized into OTC and prescription-based drugs, of which the drugs sold through prescriptions held a significant market share in 2017.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample

During the forecast period, the dermatology drugs market is forecasted to witness the fastest growth in APAC, with 9.6% CAGR. This growth can be attributed to the increasing disposable income of people in the region, which is leading to the high adoption of skincare products, including dermatological drugs. Moreover, the increase in the number of skin cancer cases in the region is contributing to the high demand for these drugs.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dermatology-drug-market

Companies operating in the dermatology drugs market are collaborating with other pharmaceutical firms to develop new and innovative products. For instance, in November 2018, Sanofi collaborated with Denali Therapeutics Inc. (Denali), a biopharmaceutical company, for the development of multiple molecules, DNL747 and DNL758, with the potential to treat a range of neurological and systemic inflammatory diseases. Under the agreement, Sanofi will pay $125 million to Denali to study the lead molecule DNL747 in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis and DNL758 in systemic inflammatory diseases, such as rheumatoid arthritis and psoriasis.

Some of the other key players in the dermatology drugs market are Celgene Corporation, Bausch Health Companies Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Allergan plc, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.

About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Biopharmaceuticals Market Size, Share, Development, Growth and Demand

The global biopharmaceuticals market was valued at $ 160,440.4 million in 2014, and it is expected to grow with a CAGR of 9.6% during the period 2015 - 2020.

The global biopharmaceuticals market is increasing, due to growing aging population. In addition, the increasing healthcare investments around the world are propelling the increase in R&D investments, which is fuelling the growth of the global biopharmaceuticals market. Furthermore, the increasing prevalence of chronic diseases due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity is also contributing to the growth in demand of biopharmaceuticals globally. On the basis of types, the global recombinant human insulin market segment is expected to witness fastest growth during the forecast period. Among the application segment, the oncology segment accounted for the largest market in the global biopharmaceuticals market in 2014; and is expected to witness fastest growth, with 11.1% CAGR during the period 2015 – 2020.

Download Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/biopharmaceuticals-market/report-sample

However, the high cost and side effects of biopharmaceuticals is a key restraint, which is adversely impacting the growth of the global biopharmaceuticals market. In addition, the entry of low cost biosimilars of existing biopharmaceuticals, also acts as a restraint in the growth of the global biopharmaceuticals market. The Asian biopharmaceuticals market is expected to witness fastest growth, with a CAGR of 10.6% during the period 2015 – 2020.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=biopharmaceuticals-market

The key companies operating in the global biopharmaceuticals market include AbbVie Inc, Sanofi, Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AstraZeneca PLC, Novartis AG, Biogen Idec , Bristol-Myers Squibb Company and Amgen Inc.



About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Nerve Repair and Regeneration Market Share Assessments for the Regional and Country Level Segments

The nerve repair and regeneration market is expected to reach $14.9 billion by 2023, growing at a CAGR of 11.9% between 2017-2023.Growing incidences of peripheral nerve injuries, increasing cases of neurological disorders, growing aging population, and technological advancements in nerve repair and regeneration products are the key drivers for the market.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/nerve-repair-and-regeneration-market/report-sample

Geographically, North America has been the largest market for nerve repair and regeneration, with the U.S. being the largest contributor to the regional market. Increasing incidence of peripheral nerve injuries and presence of technological advanced products has been driving the growth of the North American market. In Europe, Germany has been the largest contributor to the nerve repair and regeneration market, followed by the U.K. and France. The market is expected to witness highest growth in Asia-Pacific, during 2017 - 2023, owing to increasing cases of neurological disorders and increasing geriatric population.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nerve-repair-and-regeneration-market

The nerve repair and regeneration market is highly consolidated with top three players including Medtronic, Plc, Boston Scientific Corporation and St. Jude Medical, Inc. holding the major share. Medtronic Plc dominated the market in 2016. The company offers implantable neurostimulation and targeted drug delivery systems, such as SCS, DBS, GES and SNS systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

Some of the other key players in the nerve repair and regeneration market are Axogen, Inc., Baxter International Inc., Cyberonics, Inc., Integra Lifesciences Holdings Corporation, Orthomed S.A.S., Stryker Corporation and Polyganics B.V.

About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com